Increased efficiency of immunotherapy using irradiated tumor cells

Wu, Jicheng; Fitzgerald, John E.; Sonis, Stephen T.; Ravikumar, T. S.; Wilson, Richard E.

doi:10.1007/bf00199835

Cited by 2 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although, more experiments will be needed to clarify the mechanism(s) underlying this effect(s) of 7TSOG, the possibility can not be ruled out that triple vaccination boosted with 7T8OG elicits some suppressor mechanism that partial]y counteracts the augmentation of the antitumor response by induction of a suppressor subpopulation ofT cells [18,31].…”

Section: Discussionmentioning

confidence: 94%

“…In the first series of experiments our aim was to examine whether pretreatment of mice with 7T8OG, which was known to activate nonspecific immune effectors [28], and inhibit pulmonary murine melanoma tumor growth [26] would also protect mice from developing leukemia. In all experiments a dose of 150 mg/kg 7T8OG, divided into two equal injections, was administered, since this treatment regimen was found to induce optimal effector cell responses previously [17,26,31]. Results demonstrate that 7T8OG injected alone, 7 days prior to the inoculation of live tumor, was unable to prolong the survival of leukemic mice.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: Increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine

Sharma¹,

Balázs²,

Wang³

et al. 1991

Cancer Immunol Immunother

View full text Add to dashboard Cite

We have investigated the ability of a novel immunopotentiator, 7-thia-8-oxoguanosine (7T8OG) to increase the efficacy of a weakly immunogenic murine L1210 leukemia vaccine. The vaccine was prepared by irradiating L1210 leukemia cells in a cesium source with a total of 6000-R dose. DBA/2 mice were treated with 150 mg/kg 7T8OG and/or with vaccine consisting of 10(7) irradiated cells. In combination therapy, mice first received the vaccine and then were injected with 75 mg/kg 7T8OG 2 h and 4 h after vaccination. One week after the last treatment all mice were inoculated with 10(4) live leukemia cells intraperitoneally. Control, untreated mice (n = 66) injected with 10(4) live leukemia cells had a mean survival time +/- standard error of 10.5 +/- 0.2 days. Treating mice (n = 66) with one, two or three doses of 7T8OG administered i.p. 1 week apart did not increase survival (mean survival time = 10.7 days). Mice immunized with one, two or three doses of vaccine had 14.5 +/- 1.1, 45.4 +/- 6.2 and 68.3 +/- 10.6 days mean survival, respectively. 7T8OG-stimulated vaccination increased the survival dramatically. The best survival was noted when the mice were treated with 2x (vaccine + 7T8OG). Immunization of mice (n = 30) with this treatment regimen increased the mean survival to 156 +/- 10.0 days. Over 90% of mice that were treated this way had a cumulative survival time greater than 160 days. In contrast, only 12% of the mice immunized twice with the leukemia vaccine alone survived over 160 days. These results suggest a rationale for the use of this immuno-potentiator with various vaccines for a more effective immunization.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 97%

Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: Increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine

Sharma¹,

Balázs²,

Wang³

et al. 1991

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…The dose selection for irradiated MCA was based on data from earlier studies (11). Mice were observed daily for survival.…”

Section: Methodsmentioning

confidence: 99%

In vivoandin vitroeffects of β‐carotene and algae extracts in murine tumor models

Combs

Sonis

Fitzgerald

et al. 1989

Nutrition and Cancer

Self Cite

View full text Add to dashboard Cite

Phycotene, an algae extract with known antineoplastic activity, was demonstrated to prolong, but not sustain, an increased survival rate in a murine fibrosarcoma model when it was combined with immunotherapy. It was further shown that splenocytes from phycotene and beta-carotene-treated survivors could not confer protection to a fresh tumor cell challenge in virgin mice after adoptive transfer. In a series of cytotoxicity assays, phycotene combined with immunization was demonstrated to enhance cell-mediated and complement-dependent cytotoxicity in the first 14-21 days. However, after 21 days, the phycotene and immunization groups exhibited a decreased ability to mediate immune cytotoxicity compared with immunization-only controls. This may serve to explain the in vivo findings that while survival was increased early on in active immunization and phycotene-treated mice, it eventually dropped to the level of the active immunization controls.

show abstract

Increased efficiency of immunotherapy using irradiated tumor cells

Cited by 2 publications

References 9 publications

Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: Increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine

Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: Increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine

In vivoandin vitroeffects of β‐carotene and algae extracts in murine tumor models

Contact Info

Product

Resources

About